Potent antitumor effect of combination therapy with sub-optimal doses of Akt inhibitors and pomalidomide plus dexamethasone in multiple myeloma

Afuresertib (AFU), a novel inhibitor of the serine/threonine kinase AKT, has clinical efficacy as a monotherapy against hematological malignancies and is expected to be used in combination with standard therapies for multiple myeloma (MM). To develop a more effective and less toxic combination of im...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncol Lett
Autors principals: Kinoshita, Shiori, Ri, Masaki, Kanamori, Takashi, Aoki, Sho, Yoshida, Takashi, Narita, Tomoko, Totani, Haruhito, Ito, Asahi, Kusumoto, Shigeru, Ishida, Takashi, Komatsu, Hirokazu, Iida, Shinsuke
Format: Artigo
Idioma:Inglês
Publicat: D.A. Spandidos 2018
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6004690/
https://ncbi.nlm.nih.gov/pubmed/29928335
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2018.8501
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars